Skip to content

Author

Israt Jahan Mukta

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

PD-L1 Expression as a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer

Background: Immune checkpoint blockade has changed the treatment of high-risk early-stage triple-negative breast cancer (TNBC), yet the clinical role of programmed death-ligand 1 (PD-L1) expression in the neoadjuvant setting remains unsettled. PD-L1 may identify an immune-enriched tumor microenvironment and therefore c...

Naznin Nahida, Dhruba Tasnim, Israt Jahan Mukta et al. · 0 citations
Open access Aug 2026

Targeting EZH2 Oncogenic Splicing: Decoding the Regulatory Network and Antisense Correction

This study instigated a gene-specific targeted strategy by unlocking the regulatory network, and designed antisense oligonucleotides (ASOs) targeting important regulatory sites, demonstrating that ASO pharmacology is an actionable strategy for clinical development, challenging the existing paradigms in SF-mutated cance...

Md Rafikul Islam, Preeti Nagar, Naomi McNaughton et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.